HomeCompareRSMC vs ABBV

RSMC vs ABBV: Dividend Comparison 2026

RSMC yields 7.88% · ABBV yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $73.7K in total portfolio value
10 years
RSMC
RSMC
● Live price
7.88%
Share price
$25.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.7K
Annual income
$1,298.23
Full RSMC calculator →
ABBV
AbbVie Inc.
● Live price
3.18%
Share price
$208.80
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.4K
Annual income
$26,796.51
Full ABBV calculator →

Portfolio growth — RSMC vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSMCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSMC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSMC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSMC
Annual income on $10K today (after 15% tax)
$669.96/yr
After 10yr DRIP, annual income (after tax)
$1,103.50/yr
ABBV
Annual income on $10K today (after 15% tax)
$270.72/yr
After 10yr DRIP, annual income (after tax)
$22,777.03/yr
At 15% tax rate, ABBV beats the other by $21,673.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSMC + ABBV for your $10,000?

RSMC: 50%ABBV: 50%
100% ABBV50/50100% RSMC
Portfolio after 10yr
$70.5K
Annual income
$14,047.36/yr
Blended yield
19.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RSMC
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+22.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSMC buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSMCABBV
Forward yield7.88%3.18%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$33.7K$107.4K
Annual income after 10y$1,298.23$26,796.51
Total dividends collected$10.5K$65.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RSMC vs ABBV ($10,000, DRIP)

YearRSMC PortfolioRSMC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,488$788.19$11,568$447.80$80.00ABBV
2$13,139$846.25$13,518$654.97$379.00ABBV
3$14,963$904.51$16,000$967.77$1.0KABBV
4$16,973$962.71$19,240$1,448.28$2.3KABBV
5$19,182$1,020.60$23,597$2,202.04$4.4KABBV
6$21,602$1,077.95$29,655$3,414.72$8.1KABBV
7$24,249$1,134.57$38,402$5,425.87$14.2KABBV
8$27,137$1,190.26$51,587$8,884.00$24.4KABBV
9$30,281$1,244.86$72,455$15,089.50$42.2KABBV
10$33,699$1,298.23$107,366$26,796.51$73.7KABBV

RSMC vs ABBV: Complete Analysis 2026

RSMCStock

Under normal circumstances, the fund invests at least 80% of its net assets (plus borrowing for investment purposes) in equity securities of U.S. small- and mid-capitalization companies. The manager considers small- and mid-capitalization companies to be those companies having a market capitalization range within the range of companies comprising the Russell 2500 Index. The fund is non-diversified.

Full RSMC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RSMC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSMC vs SCHDRSMC vs JEPIRSMC vs ORSMC vs KORSMC vs MAINRSMC vs JNJRSMC vs MRKRSMC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.